10x Genomics, Inc. Class A Common Stock (TXG) Stock Analysis
Sector: Technology · Industry: Laboratory Analytical Instruments
AnalystsHold20 analystsStrengths
- ✓Altman Z 31.3 — safe-zone balance sheet
Risks
- ⚠SBC 15.8% of revenue — real dilution cost
- ⚠7 loss-making years in recent history
- ⚠Interest coverage -75.7× — thin debt cushion
What's happening with TXG
Price History
5-Year Weekly Candlestick Chart
Profile
Strong financial health; profitability, growth, valuation and earnings quality lag behind.
How is each axis scored?
- Valuation30/100 · Weak
- P/E vs own history (n/a)10/25
- FCF yield (1.1%)5/25
- P/S (17.4x)5/25
- EV/EBIT (n/a)10/25
- Growth12/100 · Weak
- Revenue CAGR (7.0%)12/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (n/a)0/25
- Profitability0/100 · Weak
- ROIC (-4.0%)0/25
- ROE (-2.8%)0/25
- Net margin (-3.5%)0/25
- Operating margin (-6.1%)0/25
- Financial Health75/100 · Strong
- Altman Z (31.32)25/25
- Current ratio (5.90)25/25
- Interest coverage (-75.7x)0/25
- Net cash / debt (Net cash)25/25
- Quality35/100 · Weak
- Piotroski F (4/9)10/25
- Beneish M (-2.94)25/25
- FCF conversion (n/a)0/25
- Margin stability (σ 32.8%)0/25
About 10x Genomics, Inc. Class A Common Stock
10x Genomics Inc is a life science technology company based in the United States. Show more
Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
Headquarters: PLEASANTON, CA · Employees: 1,178 · Website ↗
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
Valuation
30DP/E (TTM)—
Price / TTM EPS (own statements)
P/FCF92.0xD
Grade D: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield1.1%C
Grade C: LowTTM FCF / Market Cap — vs own 5Y history: -5.8%–5.7% · 61st pct
P/S (TTM)17.44xD
Grade D: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 1.4x–43.7x · 91st pct
EV/EBITDA—
Enterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales17.3xD
Grade D: Very expensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E—
Price / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio13.68xD
Grade D: Very expensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio—
Finnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
0EROIC-4.0%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE-2.8%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA-7.3%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-3.5%D
Grade D: LowNet Income / Revenue
Operating Margin-6.1%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin69.6%A
Grade A: PremiumGross Profit / Revenue
FCF Margin19.1%A
Grade A: HighFCF / Revenue
True FCF Margin3.4%D
Grade D: LowTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
12ERevenue CAGR7.0%C
Grade C: OkCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Implied 1Y EPS growth from forward P/E vs our TTM EPS. Sparse — only where forward estimates exist
Dilution (5Y)+18.0%D
Grade D: DilutiveShare count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue15.8%D
Grade D: HighTTM stock-based comp / TTM Revenue
Financial Health
75B+Altman Z-Score31.32A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio5.90xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio3.95xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-75.7xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT—
Leverage. <2x Low, >4x High
Debt/Equity0.00xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt—
Cash covers how much of total debt. >1 = could repay all debt from cash
Quality
35DPiotroski F-Score4/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-2.94A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability32.8%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue0.9%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.62xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
More metrics — Per Share, Balance Sheet, MarketHide additional metrics
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$4.10
Cash & short-term investments per share (Finnhub)
Book Value / Share$6.24
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt—
Total debt obligations (short + long term)
Cash & Equiv.$49.56M
Cash and short-term investments
Net Debt—
Total Debt minus Cash. Negative = Net Cash position
Total Equity$814.32M
Shareholders' equity (book value)
Asset / Liability5.04xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$11.14B
Current Market Capitalization
Beta2.06D
Grade D: High volatilityPrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
Takeaway
Company is effectively debt-free after netting cash.
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Mar 2026 · Ratio snapshot Sep 27, 2026
Key Insights: 10x Genomics, Inc. Class A Common Stock (TXG)
TXG is up 1.90% at the last close. Piotroski F-Score of 4/9 indicates mixed fundamentals for 10x Genomics, Inc. Class A Common Stock. Altman Z-Score of 31.32 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.94 suggests a low likelihood of earnings manipulation. 10x Genomics, Inc. Class A Common Stock converts about 19% of revenue into free cash flow — strong cash generation.
- Company is effectively debt-free after netting cash.
- Interest coverage of -75.7× leaves little room for earnings shocks.
- 10x Genomics, Inc. Class A Common Stock posted a net loss in 7 of 7 available completed fiscal years (2019–2025).
- At a valuation score of 30/100, TXG trades at a premium to its historical multiples.
Insider Transactions
Recent SEC Form 4 filings · 8 records
| Transaction date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Saxonov Serge Filed | Saxonov Serge | SellOpen market sale | -2800 | |
Saxonov Serge Filed | Saxonov Serge | SellOpen market sale | -9900 | |
Saxonov Serge Filed | Saxonov Serge | SellOpen market sale | -9300 | |
Saxonov Serge Filed | Saxonov Serge | SellOpen market sale | -2000 | |
Saxonov Serge Filed | Saxonov Serge | SellOpen market sale | -1000 |
Show 3 more filingsShow fewer filings
| Transaction date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
SULIMAN SHEHNAAZ Filed | SULIMAN SHEHNAAZ | SellOpen market sale | -1222 | |
SULIMAN SHEHNAAZ Filed | SULIMAN SHEHNAAZ | SellOpen market sale | -2270 | |
SULIMAN SHEHNAAZ Filed | SULIMAN SHEHNAAZ | SellOpen market sale | -1325 |
See how TXG ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all TXG moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Sep 24 | Regular | 84.80 | +12.14% | 3.08 |
| Sep 24 | After-hours | 84.92 | +12.30% | 3.12 |
| Sep 23 | Regular | 75.58 | -6.34% | -2.58 |
| Sep 23 | After-hours | 75.62 | -6.29% | -2.57 |
| Sep 21 | Regular | 79.22 | +3.42% | 2.28 |
Frequently Asked Questions about TXG
What is the current 10x Genomics, Inc. Class A Common Stock (TXG) stock price?
TXG is trading at $85.71 at the last market close, up 1.90% on the session. PreMarketPrice tracks TXG pre-market, intraday and after-hours prices.
Is TXG stock a buy right now?
PreMarketPrice's quantitative model rates 10x Genomics, Inc. Class A Common Stock's financial health at 75/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is TXG stock overvalued?
10x Genomics, Inc. Class A Common Stock trades at a trailing P/E of n/a and our valuation score rates it 30/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does 10x Genomics, Inc. Class A Common Stock report earnings?
No confirmed earnings date is currently scheduled for TXG. The Earnings section lists recent reports and updates as dates are announced.
What sector does 10x Genomics, Inc. Class A Common Stock operate in?
10x Genomics, Inc. Class A Common Stock operates in the Technology sector, within the Laboratory Analytical Instruments industry. The Related Stocks section lists sector peers for comparison.
What does 10x Genomics, Inc. Class A Common Stock do?
10x Genomics Inc is a life science technology company based in the United States.
About 10x Genomics, Inc. Class A Common Stock (TXG) Stock
10x Genomics, Inc. Class A Common Stock (TXG) is a US-listed stock operating in the Technology sector, specifically the Laboratory Analytical Instruments industry. As of the latest update, 10x Genomics, Inc. Class A Common Stock is trading at $85.71, up 1.90% on the day with a market capitalization of $11.1 billion. The financial health score for TXG is 75/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for TXG stock.
TXG Stock Analysis & Key Metrics
On PreMarketPrice, you can track 10x Genomics, Inc. Class A Common Stock (TXG) across multiple dimensions:
- Pre-market price & movement: Real-time TXG stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for TXG with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for 10x Genomics, Inc. Class A Common Stock across multiple reporting periods.
- Financial health score: A composite score of 75/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for TXG.
- Sector peers: Compare TXG against 10 other technology stocks on key financial metrics.
Is TXG a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate 10x Genomics, Inc. Class A Common Stock (TXG) as an investment. The financial health score of 75/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.10x Genomics, Inc. Class A Common Stock (TXG) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.